Should I buy or sell Delcath Systems stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks .

What is Delcath Systems' stock price target for 2024?

4 brokerages have issued 12-month target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 294.0% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts .

How have DCTH shares performed in 2024?

Delcath Systems' stock was trading at $4.16 at the beginning of 2024. Since then, DCTH shares have increased by 12.9% and is now trading at $4.6950. View the best growth stocks for 2024 here .

When is Delcath Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our DCTH earnings forecast .

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.19. The firm had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative trailing twelve-month return on equity of 563.60% and a negative net margin of 2,308.86%. During the same period in the prior year, the company posted ($0.86) earnings per share.

When did Delcath Systems' stock split?

Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DCTH

Delcath Systems (DCTH) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free DCTH Stock Alerts

$4.70

+0.22 (+4.92%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.26
▼
$5.03
50-Day Range: $3.72
▼
$5.09
52-Week Range: $2.25
▼
$7.99

Volume: 335,142 shs
Average Volume: 220,782 shs
Market Capitalization: $119.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.50

Get Delcath Systems alerts:

Delcath Systems MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 294.0% Upside
$18.50 Price Target
Short Interest: Bearish
3.68% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$100,001 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.45) to ($0.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.61 out of 5 stars

Medical Sector

432nd out of 918 stocks

Surgical & Medical Instruments Industry

42nd out of 91 stocks

3.5

Analyst's Opinion

Consensus Rating
Delcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Delcath Systems has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.68% of the outstanding shares of Delcath Systems have been sold short.
Short Interest Ratio / Days to Cover
Delcath Systems has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Delcath Systems has recently increased by 4.16%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Delcath Systems does not currently pay a dividend.
Dividend Growth
Delcath Systems does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DCTH.

1.1

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Delcath Systems this week, compared to 1 article on an average week.
Search Interest
5 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
MarketBeat Follows
7 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,001.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
21.10% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Delcath Systems are expected to grow in the coming year, from ($1.45) to ($0.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Delcath Systems is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Delcath Systems is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Delcath Systems has a P/B Ratio of 6.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Delcath Systems Stock (NASDAQ:DCTH)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

DCTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DCTH Stock News Headlines

March 21, 2024 | insidertrades.com

Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) Director Acquires 26,882 Shares of Stock

April 16, 2024 | americanbankingnews.com

Head to Head Survey: Sharps Technology (NASDAQ:STSS) & Delcath Systems (NASDAQ:DCTH)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 4, 2024 | finanznachrichten.de

Delcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2024 | finance.yahoo.com

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)

March 27, 2024 | finance.yahoo.com

Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript

March 26, 2024 | finance.yahoo.com

Delcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancements

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 26, 2024 | finanznachrichten.de

Delcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 26, 2024 | msn.com

Delcath Systems GAAP EPS of -$0.48, revenue of $0.54M

March 26, 2024 | prnewswire.com

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 25, 2024 | msn.com

Delcath Systems Q4 2023 Earnings Preview

March 23, 2024 | finance.yahoo.com

Insiders of Delcath Systems Getting Good Value On Their US$736.5k Investment

March 20, 2024 | prnewswire.com

Delcath Systems Closes $7 Million Private Placement

March 19, 2024 | prnewswire.com

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

March 19, 2024 | finanznachrichten.de

Delcath Systems, Inc.: Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

March 18, 2024 | markets.businessinsider.com

Delcath Systems Appoints Martha Rook As COO

March 18, 2024 | prnewswire.com

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

March 17, 2024 | investing.com

Delcath Systems secures $7 million in private placement

March 16, 2024 | finance.yahoo.com

DCTH Apr 2024 7.500 call

March 15, 2024 | markets.businessinsider.com

Delcath Announces $7 Mln Private Placement

March 15, 2024 | prnewswire.com

Delcath Systems Announces $7 Million Private Placement

March 8, 2024 | prnewswire.com

Delcath Systems to Participate in Upcoming Investor Conferences

February 22, 2024 | stockhouse.com

Delcath Systems Announces Healthcare Setting Locator for HEPZATO(TM) KIT (melphalan/Hepatic Delivery System)

February 22, 2024 | finance.yahoo.com

Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

February 16, 2024 | prnewswire.com

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:DCTH
CUSIP: N/A
CIK: 872912
Web: delcath.com
Phone: 212-489-2100
Fax: 212-489-2102
Employees: 76
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.50
High Stock Price Target: $21.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +288.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,680,000.00
Net Margins: -2,308.86%
Pretax Margin: -2,308.86%
Return on Equity: -563.60%
Return on Assets: -111.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.26
Quick Ratio: 2.06

Sales & Book Value

Annual Sales: $2.07 million
Price / Sales: 58.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.72 per share
Price / Book: 6.61

Miscellaneous

Outstanding Shares: 25,440,000
Free Float: 20,071,000
Market Cap: $121.09 million
Optionable: Optionable
Beta: 0.53

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Gerard J. Michel MBA (Age 61)
MS, CEO & Director
Comp: $671.6k
Dr. Johnny John M.D. (Age 59)
Senior Vice President of Clinical Operations & Medical Affairs
Comp: $472.16k
Ms. Sandra Pennell (Age 45)
Senior VP of Finance and Principal Financial & Accounting Officer
Dr. Martha S. Rook Ph.D. (Age 52)
Chief Operating Officer
Mr. David Hoffman
General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Vojislav Vukovic M.D. (Age 57)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DCTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Delcath Systems stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCTH shares.
View DCTH analyst ratings or view top-rated stocks.
What is Delcath Systems' stock price target for 2024?: 4 brokerages have issued 12-month target prices for Delcath Systems' shares. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 294.0% from the stock's current price.
View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts.
How have DCTH shares performed in 2024?: Delcath Systems' stock was trading at $4.16 at the beginning of 2024. Since then, DCTH shares have increased by 12.9% and is now trading at $4.6950.
View the best growth stocks for 2024 here.
When is Delcath Systems' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our DCTH earnings forecast.

How were Delcath Systems' earnings last quarter?: Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.19. The firm had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.48 million. Delcath Systems had a negative trailing twelve-month return on equity of 563.60% and a negative net margin of 2,308.86%. During the same period in the prior year, the company posted ($0.86) earnings per share.
When did Delcath Systems' stock split?: Shares of Delcath Systems reverse split on the morning of Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Delcath Systems?: Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCTH) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial